Century Therapeutics (NASDAQ:IPSC) Releases Earnings Results

Century Therapeutics (NASDAQ:IPSC) posted its quarterly earnings results on Thursday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07, Zacks reports. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 9.67%.

Century Therapeutics Stock Performance

Shares of NASDAQ IPSC traded up $0.01 during mid-day trading on Friday, reaching $0.47. 962,784 shares of the company traded hands, compared to its average volume of 1,416,140. The stock has a market cap of $40.80 million, a PE ratio of -1.48 and a beta of 1.80. The company’s fifty day moving average is $0.54 and its two-hundred day moving average is $0.55. Century Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $1.83.

Institutional Investors Weigh In On Century Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP raised its position in shares of Century Therapeutics by 59.2% in the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after purchasing an additional 338,902 shares during the period. Squarepoint Ops LLC grew its stake in Century Therapeutics by 483.1% in the 3rd quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after buying an additional 195,573 shares during the last quarter. Jane Street Group LLC bought a new position in Century Therapeutics in the 2nd quarter worth $248,000. Raymond James Financial Inc. acquired a new position in Century Therapeutics during the 2nd quarter worth $51,000. Finally, Qube Research & Technologies Ltd bought a new stake in Century Therapeutics during the second quarter valued at about $38,000. Institutional investors own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IPSC shares. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 20th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Century Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $3.75.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.